Immune Receptor Articles & Analysis
6 news found
Presentation Details Title: PMC-309, a highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive TME Abstract Number: 751 Presentation Type: Poster Presentation Onsite Location: Poster Hall Date: November 10, 2022 9 a.m. ...
He received his B.A. in business economics from the University of California, Santa Barbara, and holds an active CPA license. Immune-Onc also announced successful completion of dose escalation in the first-in-human clinical trial (NCT05054348) of IO-108, a novel antagonist antibody targeting the myeloid checkpoint Leukocyte Immunoglobulin-Like Receptor B2 ...
(“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the first patient has been treated with IO-108, a first-in-class myeloid checkpoint inhibitor targeting Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2, also known as ILT4), in a Phase 1 clinical ...
LAIR1 is an immune inhibitory receptor expressed on lymphocytes and myeloid cells that correlates with worse survival in several cancers. ...
Chengcheng (Alec) Zhang, Professor of Physiology at UT Southwestern Medical Center and Scientific Founder of Immune-Onc, will give an expert presentation on the LILRB/ILT family of receptors as myeloid checkpoint targets in immuno-oncology at 2:30 PM EDT. ...
The symposium will focus on the emerging landscape of technologies leveraging gamma delta T cells for anticancer therapeutics and will be moderated by Andrea van Elsas, Ph.D., chair, scientific advisory board at LAVA, and will feature presentations from leading experts in the field of gamma delta T cell immunity. Prof. Hans van der Vliet, M.D., Ph.D., professor, medical ...